These findings may explain why the approach, cisplatin chemotherapy, can lead to cure in a small subset of patients with metastatic, or advanced, bladder cancer. Researchers also believe that ...

Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of ...

Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that ...

cisplatin and vinblastine (V) in patients with advanced transitional carcinoma of the bladder. Eur Urol 1990; 18 (Suppl. 1): 5. 3. Mead GM, Russell M, Clark P et al.: A randomised trial comparing ...

Petros Grivas, MD, PhD, discusses the key trials of bladder cancer using immunotherapy he highlighted during a Case-Based ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC).

A new study from Cedars-Sinai Cancer reveals a potential way to overcome tumor resistance to a common chemotherapy drug ...

Including transurethral resection of bladder tumors, induction chemotherapy, followed by concurrent radiochemotherapy, assessment cystoscopy and consolidation radiochemotherapy. Cis: Cisplatin ...

MEDLINE 10. Coppin CM, Gospodarowicz MK, James K et al.: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer ...

The following is a summary of “Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive ...